Evidence-Based Medicine Guidelines
Terazosin for benign prostatic hyperplasia
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Terazosin for Benign Prostatic Hyperplasia." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/450513/all/Terazosin_for_benign_prostatic_hyperplasia.
Terazosin for benign prostatic hyperplasia. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. https://evidence.unboundmedicine.com/evidence/view/EBMG/450513/all/Terazosin_for_benign_prostatic_hyperplasia. Accessed November 22, 2024.
Terazosin for benign prostatic hyperplasia. (2024). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/450513/all/Terazosin_for_benign_prostatic_hyperplasia
Terazosin for Benign Prostatic Hyperplasia [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. [cited 2024 November 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/450513/all/Terazosin_for_benign_prostatic_hyperplasia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Terazosin for benign prostatic hyperplasia
ID - 450513
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/450513/all/Terazosin_for_benign_prostatic_hyperplasia
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
